CN117797140A - Application of daphne diterpene Wikstroelide E in preparation of breast cancer treatment drugs - Google Patents
Application of daphne diterpene Wikstroelide E in preparation of breast cancer treatment drugs Download PDFInfo
- Publication number
- CN117797140A CN117797140A CN202311809492.4A CN202311809492A CN117797140A CN 117797140 A CN117797140 A CN 117797140A CN 202311809492 A CN202311809492 A CN 202311809492A CN 117797140 A CN117797140 A CN 117797140A
- Authority
- CN
- China
- Prior art keywords
- wikstroelide
- breast cancer
- diterpene
- daphne
- tumor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- YTMZOVBDBJZQRD-RSRQXKISSA-N wikstroelide E Natural products O([C@@]12[C@H](C)C[C@@]3(O4)C(C)=C)[C@]4(CCCCCCC[C@H]4C)O[C@@H]3[C@@H]2[C@@H]2O[C@]2(CO)[C@@H](O)[C@@]2(O)[C@H]1[C@@H]4[C@H](C)C2=O YTMZOVBDBJZQRD-RSRQXKISSA-N 0.000 title claims abstract description 53
- YTMZOVBDBJZQRD-JWAMTPOYSA-N wikstroelide e Chemical compound O([C@@]12[C@H](C)C[C@@]3(O4)C(C)=C)[C@@]4(CCCCCCC[C@@H]4C)O[C@@H]3[C@@H]2[C@@H]2O[C@]2(CO)[C@@H](O)[C@@]2(O)[C@H]1[C@@H]4[C@H](C)C2=O YTMZOVBDBJZQRD-JWAMTPOYSA-N 0.000 title claims abstract description 53
- 206010006187 Breast cancer Diseases 0.000 title claims abstract description 43
- 208000026310 Breast neoplasm Diseases 0.000 title claims abstract description 43
- 150000004141 diterpene derivatives Chemical class 0.000 title claims abstract description 30
- 229930004069 diterpene Natural products 0.000 title claims abstract description 28
- 239000003814 drug Substances 0.000 title claims abstract description 17
- 238000011282 treatment Methods 0.000 title claims description 11
- 238000002360 preparation method Methods 0.000 title abstract description 5
- 229940079593 drug Drugs 0.000 title description 6
- 150000001875 compounds Chemical class 0.000 claims abstract description 20
- 230000000694 effects Effects 0.000 claims abstract description 14
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims abstract description 11
- 229960004316 cisplatin Drugs 0.000 claims abstract description 11
- 239000000546 pharmaceutical excipient Substances 0.000 claims abstract description 9
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 8
- 239000002246 antineoplastic agent Substances 0.000 claims abstract description 7
- 239000003937 drug carrier Substances 0.000 claims abstract description 4
- 230000004614 tumor growth Effects 0.000 claims description 5
- CGPFADLKIPZYRE-OWLUANBVSA-N daphnane Chemical compound C([C@]12CCC[C@H]1[C@]13CCC)C[C@H]4[C@]3(C)CC[C@H](C(C)C)[C@@H]1N2C4 CGPFADLKIPZYRE-OWLUANBVSA-N 0.000 claims description 4
- 238000001727 in vivo Methods 0.000 claims description 2
- 239000000126 substance Substances 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims 3
- 229940127089 cytotoxic agent Drugs 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 abstract description 32
- 230000000259 anti-tumor effect Effects 0.000 abstract description 9
- 229940041181 antineoplastic drug Drugs 0.000 abstract description 6
- 238000011725 BALB/c mouse Methods 0.000 abstract description 4
- 239000003560 cancer drug Substances 0.000 abstract description 4
- 241000699670 Mus sp. Species 0.000 description 11
- 241000699666 Mus <mouse, genus> Species 0.000 description 9
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- 230000037396 body weight Effects 0.000 description 6
- 230000002401 inhibitory effect Effects 0.000 description 5
- 238000002054 transplantation Methods 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 201000011510 cancer Diseases 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 description 2
- 241000628997 Flos Species 0.000 description 2
- 108010087230 Sincalide Proteins 0.000 description 2
- 238000000692 Student's t-test Methods 0.000 description 2
- 206010070863 Toxicity to various agents Diseases 0.000 description 2
- 241001263989 Wikstroemia Species 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 238000010609 cell counting kit-8 assay Methods 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 238000012353 t test Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 241000723435 Chamaedaphne Species 0.000 description 1
- 101800005151 Cholecystokinin-8 Proteins 0.000 description 1
- 102400000888 Cholecystokinin-8 Human genes 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 241001093501 Rutaceae Species 0.000 description 1
- 241001104043 Syringa Species 0.000 description 1
- 235000004338 Syringa vulgaris Nutrition 0.000 description 1
- 229940123237 Taxane Drugs 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 244000029687 Wikstroemia indica Species 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000002784 cytotoxicity assay Methods 0.000 description 1
- 231100000263 cytotoxicity test Toxicity 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- -1 diterpenoid compounds Chemical class 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 238000009261 endocrine therapy Methods 0.000 description 1
- 229940034984 endocrine therapy antineoplastic and immunomodulating agent Drugs 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 229930013686 lignan Natural products 0.000 description 1
- 150000005692 lignans Chemical class 0.000 description 1
- 235000009408 lignans Nutrition 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 238000000691 measurement method Methods 0.000 description 1
- 238000011242 molecular targeted therapy Methods 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000012488 sample solution Substances 0.000 description 1
- 201000000980 schizophrenia Diseases 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 229930004725 sesquiterpene Natural products 0.000 description 1
- 150000004354 sesquiterpene derivatives Chemical class 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000008227 sterile water for injection Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 238000009121 systemic therapy Methods 0.000 description 1
- DKPFODGZWDEEBT-QFIAKTPHSA-N taxane Chemical class C([C@]1(C)CCC[C@@H](C)[C@H]1C1)C[C@H]2[C@H](C)CC[C@@H]1C2(C)C DKPFODGZWDEEBT-QFIAKTPHSA-N 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses application of daphne diterpene Wikstroelide E in preparation of a medicament for treating breast cancer, and belongs to the technical field of anti-tumor. Aims at solving the problems of high dosage and unobvious effect of the prior anti-breast cancer drugs. Provides the application of the daphne diterpene Wikstroelide E in preparing a medicament for treating breast cancer. Also provided is an anti-breast cancer pharmaceutical composition comprising 0.1-99% of a daphne diterpene compound wikstroelide E, and the balance of pharmaceutically acceptable carriers and/or excipients. The Wikstrolide E can obviously inhibit the growth of the BALB/c mouse 4T1 breast cancer model tumor, and compared with a conventional antitumor drug, especially compared with cisplatin, the Wikstrolide E with smaller concentration can achieve the same effect as cisplatin, and can be used as a natural antitumor drug for treating breast cancer.
Description
Technical Field
The invention belongs to the technical field of anti-tumor, and particularly relates to application of daphne diterpene Wikstroelide E in preparation of a medicament for treating breast cancer.
Background
At present, breast cancer becomes the most common malignant tumor of females, 226 ten thousand new breast cancers in the world exceed lung cancer for the first time, and becomes the cancer species with the most morbidity, and the newly increased prevalence and mortality rate in female malignant tumors in China are respectively listed as the first place and the fourth place, so that the life health of females is seriously threatened, and the prevention and treatment significance is great.
Early breast cancer prognosis is better, and middle and late breast cancer still faces serious challenges. In recent years, the incidence of breast cancer in China rises year by year and has a tendency of younger. The main treatment means of breast cancer comprise surgery, radiotherapy, chemotherapy, endocrine therapy, molecular targeted therapy, systemic therapy and the like, and although the multidisciplinary comprehensive treatment improves the survival rate of patients, adverse reactions caused by tumor treatment are not quite a little. At present, the breast cancer has more medicaments, such as platinum, taxane and the like, which can inhibit the growth of tumors to different degrees, but have strong toxic and side effects, are easy to resist, and are easy to cause side effects such as low immune function and the like. Therefore, the search for the breast cancer resistant medicament with high safety and good curative effect has important significance.
The flos Genkwa is a dry bud of Wikstroemia indica (Wikstroemia chamaedaphne Meisn.) of Wikstroemia of Rutaceae, and has effects of relieving cough, relieving asthma, and removing water retention. Is mainly used for resisting early pregnancy, schizophrenia, arrhythmia, hepatitis virus and the like. The flos Genkwa mainly contains diterpenoid, flavonoid, lignans, sesquiterpenes, etc. Among these diterpenoid compounds, the most representative compounds in the yellow lilac daphne flower bud.
Disclosure of Invention
Aiming at the problems of high dosage and unobvious effect of the prior anti-breast cancer drugs, the invention provides a new application of daphne diterpene Wikstroelide E in medicine, and particularly provides an application of daphne diterpene Wikstroelide E as an anti-breast cancer drug. The diterpene antitumor effect is evaluated by directly constructing a tumor model in a normal mouse, the dosage concentration of the diterpene is very low, and the antitumor effect is realized by regulating tumor immunity.
The invention adopts the following technical scheme:
the chemical drugs used in the invention are: wikstroelide E
The dosage of the daphnane diterpene Wikstroelide E is 0.01-0.05 mg/mL.
The structural formula of the compound is as follows:
a pharmaceutical composition for treating breast cancer contains daphne diterpene compound wikstroelide E. The daphnane diterpenoid compound wikstroelide E can also be directly used as an anti-breast cancer drug.
An anti-breast cancer pharmaceutical composition contains 0.1-99% of daphne diterpene compounds wikstroelide E and the balance of pharmaceutically acceptable carriers and/or excipients which are non-toxic and inert to human and animals.
The pharmaceutically acceptable carriers or excipients are one or more solid, semi-solid and liquid diluents, fillers and pharmaceutical formulation adjuvants. The pharmaceutical composition of the present invention is used in the form of a unit weight dose. The medicine of the present invention may be administered via injection (intravenous injection, intramuscular injection) and orally.
Compared with the prior art, the invention has the following advantages:
the Wikstroelide E provided by the invention can be used as an anti-tumor drug to obviously inhibit the growth of tumors.
The Wikstroelide E provided by the invention is used as an anti-tumor drug, and the effect of the Wikstroelide E can be the same as that of the cisplatin serving as a conventional anti-tumor drug at a lower concentration.
The Wikstroelide E provided by the invention is used as an anti-tumor drug, and the administration concentration for producing a better anti-tumor effect is 0.25mg/kg.
Drawings
FIG. 1 is a graph showing the drug toxicity of daphne diterpene Wikstroelide E on 4T1 cells.
FIG. 2 is the effect of daphne diterpene Wikstroelide E and cisplatin on tumor volume in a model of balb/c mouse breast cancer transplantable tumor.
FIG. 3 is the effect of daphne diterpene Wikstroelide E and cisplatin on tumor weight in a balb/c mouse breast cancer transplant tumor model.
Detailed Description
The invention will be described in detail below with reference to the drawings in connection with embodiments.
According to the invention, by means of a mouse tumor-bearing model, the anti-tumor curative effect of Wikstroelide E is evaluated, and further the Wikstroelide E is found to be capable of remarkably inhibiting tumor growth.
In the following examples, wikstroelide E was derived from the flower of Genkwa (harvested in Jiang county, shanxi province).
Example 1: experiment of drug toxicity of daphne diterpene compound wikstroelide E on 4T1 cells.
Cytotoxicity assay of the compound wikstroelide E:
after centrifugation of the cells, the supernatant was removed, resuspended in medium, 100. Mu.L of cell suspension was prepared in 96-well plates and the plates were pre-incubated in an incubator for 12 hours (37 ℃,5% CO) 2 ) Adding sample solutions with different concentrations and diluted by a multiple ratio, continuously culturing for 24 hours, detecting the cell survival rate by a CCK-8 method, determining the influence of the sample on the cell growth, calculating TC50, and determining the concentration of the sample with the cell activity of more than or equal to 90 percent for further detecting the anti-tumor effect of the dioxane diterpene compound wikstroelide E on the BALB/c mouse transplanted 4T1 breast cancer cell transplanted tumor model.
CCK8 method detection steps: after the cells were cultured by the test, 10. Mu.L of CCK-8 solution was added to each well, and the cells were cultured in an incubator for 3 hours, and the absorbance at 450nm was measured by a microplate reader. The IC50 of the drug was calculated using SPSS 17.0. The experimental results are shown in FIG. 1.
After treatment of 4T1 cells with 0.5, 1, 2.5, 5, 10, 20, 40. Mu.M wikstroelide E, the cell viability was (97.73.+ -. 1.18)%, (104.00.+ -. 2.77)%, (105.37.+ -. 0.90)%, (105.23.+ -. 2.03)%, (99.91.+ -. 0.42)%, (101.96.+ -. 0.02)%, and (101.88.+ -. 2.88)%, respectively.
Example 2: antitumor effect of daphnane diterpene compound wikstroelide E on BALB/c mice transplanted 4T1 breast cancer cell transplantation tumor model.
Wikstroelide E was formulated to a concentration of 0.05mg/mL, 0.02mg/mL, 0.01mg/mL working fluid, and the amount of the working fluid administered to the mice was 100. Mu.L/day (physiological saline) based on the body weight of the mice (2.5. Mu.g, 1. Mu.g, 0.5. Mu.g per 10g body weight), and the mice were given by intraperitoneal injection: the dosage of cisplatin is as follows: 2.5mg/kg, i.e. every 10g body weight, 25 μg of drug is administered every other day.
Tumor volume measurement method: every two days, the same vernier caliper is used by a fixing person to measure the tumor long diameter and the tumor short diameter at regular time, and the volume is calculated according to the following formula
Volume (mm) 3 ) = (major axis. Minor axis 2 )÷2
Test section:
1. culture of breast cancer cell lines: the 4T1 cell line was cultured with 1640 containing 10% fetal bovine serum, 1% streptomycin and penicillin based on 37℃and 5% CO 2 Culturing under the condition, and constructing an in vivo transplantation tumor model.
2. Construction of breast cancer model: female BALB/c mice (body weight, 18-20 g) were inoculated subcutaneously with breast cancer cell lines 1X 10 in the inguinal region of the left lower limb 6 And each. When the tumor volume is as long as about 100mm 3 For research.
Grouping and intervention: the tumor-bearing mice are equally divided into 6 groups according to tumor volume, and the intervention is as follows: model group (physiological saline injection), low dose Wikstrolide E group (Wikstrolide E was injected intraperitoneally at study start day 1-21, once daily, 0.05 mg/kg), medium dose Wikstrolide E group (Wikstrolide E was injected intraperitoneally at study start day 1-21, once daily, 0.10mg/kg, once daily), high dose Wikstrolide E group (Wikstrolide E was injected intraperitoneally at study start day 1-21, once daily, 0.25 mg/kg), control group (cisplatin was injected intraperitoneally at study start day 1-21, once daily, 2.5mg/kg, once daily), low dose Wikstrolide E combination group (Wikstrolide E was injected intraperitoneally at study start day 1-21, once daily, while cisplatin was injected intraperitoneally at study start day 1-21, once daily, 2.5mg/kg, once daily), tumor volume was measured every two days during study, and mice were weighed after tumor shedding.
3. Wikstroelide E can obviously inhibit the growth of tumors in mice
3.1 mouse general State
The general situation of mice during observation is generally good, and part of mice have reduced mobility and eating with the increase of tumor mass in the later period of observation. The weight of the mice was obviously reduced before and after administration, the average weight of the mice was reduced by 15% after 21 days, and the weights of the other mice were not significantly changed, as shown in Table 1.
TABLE 1 variation of drug on mouse body weight during Wikstroelide E treatment (relative body weight,%)
3.2 Tumor inhibiting effect of Wikstroelide E on breast cancer
The inhibition rate of Wikstroelide E (0.25 mg/kg) on breast cancer transplants was 38.10%, while the inhibition rate of cisplatin on breast cancer transplants was 38.10% (p=0.0002 compared to model group), and the inhibition effect of high dose Wikstroelide E group on breast cancer transplants was consistent with cisplatin. The single factor ANOVA analysis results show that the high dose Wikstroelide E group has better anti-tumor effect (p=0.001) on breast cancer transplants. The results of the inter-group comparison using the t-test showed that the tumor weight of the high dose Wikstroelide E group was significantly lower than that of the model group (p=0.0001). (see Table 2, tables 3 and 4, and figures 1 and 2 of the drawings for details).
TABLE 2 tumor inhibiting effect of Wikstroelide E on mouse breast cancer transplantation tumor model
| Group (mg/kg) | Average tumor weight (g) | Tumor inhibition rate (%) |
| Model group | 1.16±0.11 | - |
| Low dose group | 0.91±0.09 | 21.41 |
| Medium dose group | 0.93±0.10 | 19.78 |
| High dose group | 0.70±0.09 | 40.15 |
| Control group | 0.69±0.03 | 40.41 |
| Control group + low dose group | 0.57±0.07 | 50.99 |
TABLE 3 tumor inhibiting effect of Wikstroelide E on mouse breast cancer transplantation tumor model (inter-group difference, t-test, p-value)
TABLE 4 tumor inhibiting effect of Wikstroelide E on mouse breast cancer transplantation tumor model (one-way ANOVA test)
Example 3: after the compound wikstroelide E is dissolved by a small amount of DMSO, water for injection is added conventionally, fine filtration, encapsulation and sterilization are carried out, and injection is prepared.
Example 4: dissolving the compound wikstroelide E with a small amount of DMSO, dissolving in sterile water for injection, stirring to dissolve, filtering with a sterile suction filter funnel, performing sterile fine filtration, packaging in ampoule, freeze-drying at low temperature, and sealing to obtain powder for injection.
Example 5: the compound wikstroelide E is added with excipient according to the weight ratio of 9:1 to prepare powder.
Example 6: the compound wikstroelide E is added with excipient according to the weight ratio of 5:1, and is granulated and tableted.
Example 7: the compound wikstroelide E is prepared into oral liquid according to the conventional oral liquid preparation method.
Example 8: the compound wikstroelide E is respectively added with excipient according to the weight ratio of 5:1 to prepare capsules.
Example 9: the compound wikstroelide E is respectively added with excipient according to the weight ratio of 3:1 to prepare capsules.
Example 10: the compound wikstroelide E is added with excipient according to the weight ratio of 5:1 to prepare the granule.
What is not described in detail in the present specification belongs to the prior art known to those skilled in the art. While the foregoing describes illustrative embodiments of the present invention to facilitate an understanding of the present invention by those skilled in the art, it should be understood that the present invention is not limited to the scope of the embodiments, but is to be construed as protected by the accompanying claims insofar as various changes are within the spirit and scope of the present invention as defined and defined by the appended claims.
Claims (7)
1. Application of daphne diterpene Wikstroelide E in preparing medicine for treating breast cancer is provided.
2. The use of daphne diterpene Wikstroelide E according to claim 1 in the manufacture of a medicament for the treatment of breast cancer, characterized in that: the dosage of the daphnane diterpene Wikstroelide E is 0.01-0.05 mg/mL.
3. The use of daphne diterpene Wikstroelide E according to claim 1 in the manufacture of a medicament for the treatment of breast cancer, characterized in that: the chemical structural formula of the daphne diterpene Wikstroelide E is as follows:
4. the use of daphne diterpene Wikstroelide E according to claim 1 in the manufacture of a medicament for the treatment of breast cancer, characterized in that: the daphne diterpene Wikstroelide E significantly inhibited tumor growth in vivo.
5. The use according to claim 4, wherein the wikstrolide E is present in a concentration of 0.25mg/kg to achieve the same effect as cisplatin, a conventional chemotherapeutic agent.
6. A pharmaceutical composition for treating breast cancer contains daphne diterpene compound wikstroelide E.
7. The pharmaceutical composition for treating breast cancer according to claim 6, wherein the pharmaceutical composition comprises 0.1-99% of the daphne diterpene compound wikstroelide E and the balance of pharmaceutically acceptable carriers and/or excipients.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202311809492.4A CN117797140A (en) | 2023-12-26 | 2023-12-26 | Application of daphne diterpene Wikstroelide E in preparation of breast cancer treatment drugs |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202311809492.4A CN117797140A (en) | 2023-12-26 | 2023-12-26 | Application of daphne diterpene Wikstroelide E in preparation of breast cancer treatment drugs |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN117797140A true CN117797140A (en) | 2024-04-02 |
Family
ID=90424809
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202311809492.4A Pending CN117797140A (en) | 2023-12-26 | 2023-12-26 | Application of daphne diterpene Wikstroelide E in preparation of breast cancer treatment drugs |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN117797140A (en) |
-
2023
- 2023-12-26 CN CN202311809492.4A patent/CN117797140A/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101612400A (en) | 1 application of receptor antagonist in antitumor of angiotensin | |
| JP2019524637A (en) | Concomitant drugs with antitumor drug effects | |
| EP0986378A1 (en) | Phorbol esters as anti-neoplastic agents | |
| CN107260734B (en) | Compound pharmaceutical composition with anti-lung cancer effect and application thereof | |
| KR100310121B1 (en) | Treatment of tumor diseases using thiazopurine and ribavirin | |
| CN101485665B (en) | Novel medical use of cucurbitacin | |
| CN117797140A (en) | Application of daphne diterpene Wikstroelide E in preparation of breast cancer treatment drugs | |
| CN108295085B (en) | Application of protodioscin in preparation of drug-resistant osteosarcoma drug | |
| EP2902028A1 (en) | Drug composition for treating tumors and application thereof | |
| CN111494385B (en) | Medicine for treating ovarian cancer and preparation method and application thereof | |
| CN110575450B (en) | Application of 2, 5-furandimethanol in preparation of antitumor drugs | |
| CN111558045A (en) | Medicine composition for treating lung cancer | |
| CN113663081A (en) | Application of oroxylin and PD-1/PD-L1 inhibitor in preparation of liver cancer treatment drug | |
| CN113786491A (en) | An anti-tumor combined preparation containing tetrandrine, dihydroquercetin or quercetin | |
| CN107412736B (en) | Anti-tumor combined medicine and application thereof in preparing anti-cancer medicine | |
| CN1120002C (en) | Application of ammonium nilrate in pharmaceutical industry, food and health-care product | |
| CN111821303A (en) | Application of vortioxetine and salts thereof in preparation of antitumor drugs | |
| CN111265555A (en) | Application of ganoderma lucidum spore extract in relieving gastrointestinal side effects caused by chemotherapeutic drugs | |
| CN113440534A (en) | Application of verbascoside in preparation of medicines | |
| CN110693903B (en) | Medicine for treating acute monocytic leukemia and application of arsenic trioxide and dihydroartemisinin | |
| CN111840523B (en) | An anticancer pharmaceutical composition containing active protein and active fatty acid | |
| CN115364076B (en) | Application of diterpenoid compound DB-022133 in preparation of medicines for treating gastric cancer | |
| CN111728960B (en) | Application of bisoprolol fumarate and docetaxel in preparation of antitumor drugs | |
| CN111249298B (en) | Anticancer pharmaceutical composition containing maduramicin and cisplatin | |
| CN111544580B (en) | Anti-cancer pharmaceutical composition |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |